VIVO تصريحات هيئة الأوراق المالية والبورصات - Meridian Bioscience Inc.- التقرير السنوي، بيان التوكيل، نشرة الإصدار

الإحصائيات الأساسية

LEI	549300ELSRZEFFFRX195
CIK	794172

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Meridian Bioscience Inc.

SEC Filings (Chronological Order)

توفر هذه الصفحة قائمة كاملة ومرتبة ترتيبًا زمنيًا لتصريحات هيئة الأوراق المالية والبورصات، باستثناء تصريحات الملكية التي نقدمها في مكان آخر.

February 13, 2023	15-12G	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 0-14902 MERIDIAN BIOSCIENCE, INC. (Exact name of registrant as specified in
February 9, 2023	10-Q	SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended December 31 , 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION Table of Contents SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended December 31 , 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-14902 MERIDIAN BIOSCI
February 9, 2023	SC 13G/A	VIVO / Meridian Bioscience, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv01407-meridianbiosciencein.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 13)* Name of issuer: Meridian Bioscience Inc. Title of Class of Securities: Common Stock CUSIP Number: 589584101 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box
February 3, 2023	EX-99.1	JOINT FILING AGREEMENT EXHIBIT 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the statement on Schedule 13D with respect to the Shares of Meridian Bioscience, Inc dated as of January 31, 2023 is, and any amendments thereto (including amendments on Schedule 13D) signed by each of the undersigned shall be, filed on behalf of each of us pursuant to and in accordance with the previsions of Rule13d-1(k) under
February 3, 2023	SC 13D/A	VIVO / Meridian Bioscience, Inc. / Magnetar Financial LLC - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 4)* Meridian Bioscience, Inc. (Name of Issuer) Common Stock, no par value (Title of Class of Securities) 589584101 (CUSIP Number of Class of Securities) David J. Snyderman Magnetar Capital LLC 1603 Orrington Ave. Evanston, Illinois 60201 (847) 905-4400 (Nam
February 3, 2023	EX-99.2	Power of Attorney, dated as of December 22, 2022 filed by the Reporting Persons on February 3, 2023. EXHIBIT 99.2 LIMITED POWER OF ATTORNEY Know all by these present, that I, David J. Snyderman, hereby make, constitute and appoint each of Michael Turro, Karl Wachter and Hayley Stein, or any of them acting individually, and with full power of substitution, as my true and lawful attorney-in-fact for the purpose of executing in my name, (a) in my personal capacity or (b) in my capacity as Manager or
February 2, 2023	S-8 POS	As filed with the Securities and Exchange Commission on February 2, 2023 As filed with the Securities and Exchange Commission on February 2, 2023 Registration Statement No.
February 2, 2023	POS AM	As filed with the Securities and Exchange Commission on February 2, 2023 As filed with the Securities and Exchange Commission on February 2, 2023 Registration Nos.
February 2, 2023	S-8 POS	As filed with the Securities and Exchange Commission on February 2, 2023 S-8 POS As filed with the Securities and Exchange Commission on February 2, 2023 Registration Statement No.
February 2, 2023	S-8 POS	As filed with the Securities and Exchange Commission on February 2, 2023 S-8 POS As filed with the Securities and Exchange Commission on February 2, 2023 Registration Statement No.
February 2, 2023	S-8 POS	As filed with the Securities and Exchange Commission on February 2, 2023 S-8 POS As filed with the Securities and Exchange Commission on February 2, 2023 Registration Statement No.
February 2, 2023	POS AM	As filed with the Securities and Exchange Commission on February 2, 2023 As filed with the Securities and Exchange Commission on February 2, 2023 Registration Nos.
February 2, 2023	S-8 POS	As filed with the Securities and Exchange Commission on February 2, 2023 As filed with the Securities and Exchange Commission on February 2, 2023 Registration Statement No.
February 2, 2023	POS AM	As filed with the Securities and Exchange Commission on February 2, 2023 As filed with the Securities and Exchange Commission on February 2, 2023 Registration Nos.
February 2, 2023	S-8 POS	As filed with the Securities and Exchange Commission on February 2, 2023 As filed with the Securities and Exchange Commission on February 2, 2023 Registration Statement No.
February 2, 2023	S-8 POS	As filed with the Securities and Exchange Commission on February 2, 2023 As filed with the Securities and Exchange Commission on February 2, 2023 Registration Statement No.
February 2, 2023	S-8 POS	As filed with the Securities and Exchange Commission on February 2, 2023 As filed with the Securities and Exchange Commission on February 2, 2023 Registration Statement No.
February 2, 2023	S-8 POS	As filed with the Securities and Exchange Commission on February 2, 2023 S-8 POS As filed with the Securities and Exchange Commission on February 2, 2023 Registration Statement No.
February 2, 2023	S-8 POS	As filed with the Securities and Exchange Commission on February 2, 2023 S-8 POS As filed with the Securities and Exchange Commission on February 2, 2023 Registration Statement No.
February 2, 2023	S-8 POS	As filed with the Securities and Exchange Commission on February 2, 2023 As filed with the Securities and Exchange Commission on February 2, 2023 Registration Statement No.
February 2, 2023	S-8 POS	As filed with the Securities and Exchange Commission on February 2, 2023 As filed with the Securities and Exchange Commission on February 2, 2023 Registration Statement No.
February 2, 2023	POS AM	As filed with the Securities and Exchange Commission on February 2, 2023 POS AM As filed with the Securities and Exchange Commission on February 2, 2023 Registration Nos.
February 2, 2023	POS AM	As filed with the Securities and Exchange Commission on February 2, 2023 As filed with the Securities and Exchange Commission on February 2, 2023 Registration Nos.
February 1, 2023	8-K	Changes in Control of Registrant, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Material Modification to Rights of Security Holders, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 31, 2023 MERIDIAN BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Ohio 0-14902 31-0888197 (State or Other Jurisdiction of Incorporation) (Commission Fi
February 1, 2023	EX-3.2	Amended and Restated Code of Regulations of Meridian Bioscience, Inc. Exhibit 3.2 AMENDED AND RESTATED CODE OF REGULATIONS OF MERIDIAN BIOSCIENCE, INC. (An Ohio Corporation) ARTICLE I – FORMATION 1.1 Legal Name. The legal name of the corporation is Meridian Bioscience, Inc., hereinafter referred to as “Corporation”. 1.2 Legal Purpose. The Corporation has been formed for the following legal purpose: Formed for any purpose or purposes for which individuals lawfully ma
February 1, 2023	EX-10.2	Revolving Credit Facility Credit Agreement, dated January 31, 2023, by and between, among others, Columbus Holding Company, Madeira Acquisition Corp., Meridian Bioscience, Inc. and PNC Bank, National Association Exhibit 10.2 Execution Version $50,000,000 REVOLVING CREDIT FACILITY CREDIT AGREEMENT dated as of January 31, 2023 among COLUMBUS HOLDING COMPANY, as Holdings, MADEIRA ACQUISITION CORP., as the Initial Borrower, immediately after giving effect to the Merger, MERIDIAN BIOSCIENCE, INC., as the Borrower, THE LENDERS PARTY HERETO, and PNC BANK, NATIONAL ASSOCIATION, as Administrative Agent TABLE OF CO
February 1, 2023	EX-10.1	Term Loan Credit Agreement, dated January 31, 2023, by and between, among others, Columbus Holding Company, Madeira Acquisition Corp., Meridian Bioscience, Inc. and Standard Chartered Bank Exhibit 10.1 Execution Version TERM LOAN CREDIT AGREEMENT dated as of January 31, 2023 among COLUMBUS HOLDING COMPANY, as Holdings, MADEIRA ACQUISITION CORP., as the Initial Borrower, immediately after giving effect to the Merger, MERIDIAN BIOSCIENCE, INC., as the Borrower, THE LENDERS PARTY HERETO, STANDARD CHARTERED BANK, as Administrative Agent, STANDARD CHARTERED BANK, EXPORT-IMPORT BANK OF KO
February 1, 2023	EX-3.1	Second Amended and Restated Certificate of Incorporation of Meridian Bioscience, Inc. Exhibit 3.1 Attachment to Certificate of Merger SECOND AMENDED AND RESTATED ARTICLES OF INCORPORATION OF MERIDIAN BIOSCIENCE, INC. The following Second Amended and Restated Articles of Incorporation supersede the previously existing Amended Articles of Incorporation of Meridian Bioscience, Inc. (the “Company”). ARTICLE I NAME The name of the Company is Meridian Bioscience, Inc. ARTICLE II PRINCIPA
February 1, 2023	EX-99.1	SD Biosensor and SJL Partners Complete Transaction to Acquire Meridian Bioscience Exhibit 99.1 For Immediate Release SD Biosensor and SJL Partners Complete Transaction to Acquire Meridian Bioscience CINCINNATI, OHIO & SEOUL, SOUTH KOREA, January 31, 2023 (PRNewswire) – Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, and SD Biosensor, Inc. (“SDB”) (KOSE: A137310) and SJL Partners LLC (“SJL”) (col
January 27, 2023	10-K/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED SEPTEMBER 30, 2022. ☐ TRANSITION REPORT PURSUANT TO S Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED SEPTEMBER 30, 2022. ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File No. 0-14902 MERIDIAN BIO
January 10, 2023	SC 13D/A	VIVO / Meridian Bioscience, Inc. / Magnetar Financial LLC - SC 13D/A Activist Investment SC 13D/A 1 tm233063d1sc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* Meridian Bioscience, Inc. (Name of Issuer) Common Stock, no par value (Title of Class of Securities) 589584101 (CUSIP Number of Class of Securities) David J. Snyderman Magnetar Capital LLC 1603 Orrington Ave. Eva
January 10, 2023	EX-99.1	JOINT FILING AGREEMENT EX-99.1 2 tm233063d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k), as promulgated under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them a Statement on Schedule 13D (including amendments thereto) with regard to the common stock of Meridian Bioscience, Inc., and further agree t
December 12, 2022	EX-2.1	Letter Agreement, dated December 9, 2022, by and among Meridian Bioscience, Inc, SD Biosensor, Inc., Columbus Holding Company, and Madeira Acquisition Corp. EX-2.1 Exhibit 2.1 MERIDIAN BIOSCIENCE, INC. 3471 River Hills Dr Newtown, OH 45244 December 9, 2022 SD Biosensor, Inc. Giheung ICT-Valley A-dong 58 Giheung-ro, Giheung-gu Yongin, 16976, Korea Attention: Eunhae Yi and HK Yu [email protected]; [email protected] Columbus Holding Company c/o SD Biosensor, Inc. Giheung ICT-Valley A-dong 58 Giheung-ro, Giheung-gu Yongin, 16976, Korea Attention
December 12, 2022	EX-99.1	Meridian Bioscience Announces Anticipated Closing Date of the Pending Merger EX-99.1 Exhibit 99.1 For Immediate Release Meridian Bioscience Announces Anticipated Closing Date of the Pending Merger CINCINNATI, OHIO, December 12, 2022 (PRNewswire) – Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced that it has entered into a side letter with the buyer, setting the closing date of Meri
December 12, 2022	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 12, 2022 MERIDIAN BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Ohio 0-14902 31-0888197 (State or Other Jurisdiction of Incorporation) (Commission F
December 2, 2022	SC 13D/A	VIVO / Meridian Bioscience, Inc. / Magnetar Financial LLC - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* Meridian Bioscience, Inc. (Name of Issuer) Common Stock, no par value (Title of Class of Securities) 589584101 (CUSIP Number of Class of Securities) David J. Snyderman Magnetar Capital LLC 1603 Orrington Ave. Evanston, Illinois 60201 (847) 905-4400 (Nam
November 22, 2022	EX-21	List of Subsidiaries of the Registrant (Filed herewith) EX-21 Exhibit 21 Subsidiaries of the Registrant 1. Meridian Bioscience Corporation, an Ohio corporation 2. Meridian Life Science, Inc., a Maine corporation 3. Meridian Bioscience Europe, s.r.l., an Italian corporation 4. Meridian Bioscience Europe S.A., a Belgian corporation 5. Meridian Bioscience Europe B.V., a Dutch corporation 6. Meridian Bioscience UK Ltd., a United Kingdom corporation 7. Meri
November 22, 2022	EX-99.1	FOURTH QUARTER AND FISCAL 2022 OPERATING RESULTS (In Thousands, Except per Share Data) EX-99.1 Exhibit 99.1 For Immediate Release MERIDIAN BIOSCIENCE REPORTS FOURTH QUARTER AND FULL YEAR FISCAL 2022 OPERATING RESULTS CINCINNATI, OHIO November 22, 2022 (PRNewswire) — Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced financial results for the fourth quarter and fiscal year ended September 30, 2022. Fourth Quarter 2022 Highlights (Comparison to Fourth Quarter Fiscal 2021): • Con
November 22, 2022	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED SEPTEMBER 30, 2022. ☐ TRANSITION REPORT PURSUANT TO SEC Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED SEPTEMBER 30, 2022. ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File No. 0-14902 MERIDIAN BIOSC
November 22, 2022	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 22, 2022 MERIDIAN BIOSCIENC UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 22, 2022 MERIDIAN BIOSCIENCE, INC.
November 3, 2022	EX-99.2	JOINT FILING AGREEMENT Exhibit 99.2 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k), as promulgated under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them a Statement on Schedule 13D (including amendments thereto) with regard to the common stock of Meridian Bioscience, Inc., and further agree that this Joint Filing Agreement be included
November 3, 2022	SC 13D/A	VIVO / Meridian Bioscience, Inc. / Magnetar Financial LLC - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Meridian Bioscience, Inc. (Name of Issuer) Common Stock, no par value (Title of Class of Securities) 589584101 (CUSIP Number of Class of Securities) David J. Snyderman Magnetar Capital LLC 1603 Orrington Ave. Evanston, Illinois 60201 (847) 905-4400 (Nam
October 28, 2022	SC 13D/A	VIVO / Meridian Bioscience, Inc. / Impactive Capital LP - AMENDMENT NO. 4 TO THE SCHEDULE 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 4)1 Meridian Bioscience, Inc. (Name of Issuer) Common Shares, no par value (Title of Class of Securities) 589584101 (CUSIP Number) LAUREN TAYLOR WOLFE CHRI
October 18, 2022	SC 13D/A	VIVO / Meridian Bioscience, Inc. / Impactive Capital LP - AMENDMENT NO. 3 TO THE SCHEDULE 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 3)1 Meridian Bioscience, Inc. (Name of Issuer) Common Shares, no par value (Title of Class of Securities) 589584101 (CUSIP Number) LAUREN TAYLOR WOLFE CHRI
October 11, 2022	8-K	Other Events, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 10, 2022 MERIDIAN BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Ohio 0-14902 31-0888197 (State or Other Jurisdiction of Incorporation) (Commission Fi
September 30, 2022	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State
September 30, 2022	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 30, 2022 MERIDIAN BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Ohio 0-14902 31-0888197 (State or Other Jurisdiction of Incorporation) (Commission
September 19, 2022	SC 13D/A	VIVO / Meridian Bioscience, Inc. / Impactive Capital LP - AMENDMENT NO. 2 TO THE SCHEDULE 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO ? 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO ? 240.13d-2(a) (Amendment No. 2)1 Meridian Bioscience, Inc. (Name of Issuer) Common Shares, no par value (Title of Class of Securities) 589584101 (CUSIP Number) LAUREN TAYLOR WOLFE CHRI
September 19, 2022	EX-99.1	JOINT FILING AGREEMENT Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k), as promulgated under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them a Statement on Schedule 13D (including amendments thereto) with regard to the common stock of Meridian Bioscience, Inc., and further agree that this Joint Filing Agreement be included
September 19, 2022	SC 13D	VIVO / Meridian Bioscience, Inc. / Magnetar Financial LLC - SC 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Meridian Bioscience, Inc. (Name of Issuer) Common Stock, no par value (Title of Class of Securities) 589584101 (CUSIP Number of Class of Securities) Alec N. Litowitz Magnetar Capital LLC 1603 Orrington Ave. Evanston, Illinois 60201 (847) 905-4400 (Name,
September 8, 2022	DEFM14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defi
September 7, 2022	SC 13D/A	VIVO / Meridian Bioscience, Inc. / Impactive Capital LP - AMENDMENT NO. 1 TO THE SCHEDULE 13D Activist Investment SC 13D/A 1 sc13da11223600409072022.htm AMENDMENT NO. 1 TO THE SCHEDULE 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 1)1 Meridian Bioscience, Inc. (Name of Issuer) Common Shares, no par value (Titl
August 25, 2022	EX-FILING FEES	Calculation of Filing Fee Table (Form Type) MERIDIAN–BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Table 1 – Transaction Valuation Transaction Valuation Fee Rate Amount of Filing Fee Fees to be Paid $1,532,313,712 (1)(2) 0.0 Calculation of Filing Fee Table SCHEDULE?14A (Form Type) MERIDIAN?BIOSCIENCE, INC.
August 25, 2022	PREM14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defi
August 5, 2022	EX-99.1	INTERIM UNAUDITED OPERATING RESULTS (In Thousands, Except per Share Data) Exhibit 99.1 For Immediate Release MERIDIAN BIOSCIENCE REPORTS THIRD QUARTER FISCAL 2022 OPERATING RESULTS CINCINNATI, OHIO August 5, 2022 (PRNewswire) ? Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced financial results for the third quarter ended June 30, 2022. Third Quarter Fiscal 2022 Highlights (Comparison to Third Quarter Fiscal 2021): ? Consolidated net revenues totaled $67.8 millio
August 5, 2022	10-Q	SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 O Table of Contents SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-14902 MERIDIAN BIOSCIENCE,
August 5, 2022	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 5, 2022 MERIDIAN BIOSCIENCE, INC.
July 29, 2022	EX-99.1	Meridian Bioscience Receives Exhibit 99.1 For Immediate Release Meridian Bioscience Receives Re-Authorization from FDA for its Revogene? SARS-CoV-2 Molecular Assay CINCINNATI, OHIO, July 29, 2022 (PRNewswire) ? Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced that it received re-authorization of its Emergency Use Authorization (EUA) f
July 29, 2022	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 29, 2022 MERIDIAN BIOSCIENCE, INC.
July 8, 2022	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State
July 7, 2022	EX-2.1	Agreement and Plan of Merger, dated as of July 7, 2022, by and among Meridian Bioscience, Inc., SD Biosensor, Inc., Columbus Holding Company, and Madeira Acquisition Corp.* Exhibit 2.1 AGREEMENT AND PLAN OF MERGER by and among SD BIOSENSOR, INC., COLUMBUS HOLDING COMPANY, MADEIRA ACQUISITION CORP., and MERIDIAN BIOSCIENCE, INC. dated as of July 7, 2022 TABLE OF CONTENTS Page Article I THE MERGER 2 Section 1.1 The Merger 2 Section 1.2 Closing 2 Section 1.3 Effective Time 2 Section 1.4 Effect of the Merger 2 Section 1.5 Articles of Incorporation and Regulations of the
July 7, 2022	EX-99.1	Meridian Bioscience Announces Preliminary Results for Fiscal 2022 Third Quarter Exhibit 99.1 Meridian Bioscience Announces Preliminary Results for Fiscal 2022 Third Quarter CINCINNATI, OH, July 7, 2022 (PRNewswire) ? Meridian Bioscience, Inc. (?Meridian? or the ?Company?) (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, today provided preliminary results for its third quarter of fiscal 2022. For the third quarter of fis
July 7, 2022	EX-10.1	Form of Indemnification Agreement Exhibit 10.1 DIRECTOR INDEMNIFICATION AGREEMENT This Director Indemnification Agreement, dated as of July , 2022 (this ?Agreement?), is made by and between Meridian Bioscience, Inc., an Ohio corporation (the ?Company?), and (?Indemnitee?), who is a director of the Company. RECITALS: A. Section 1701.59 of the Ohio Revised Code (the ?ORC?) provides that the business and affairs of a corporation shal
July 7, 2022	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State
July 7, 2022	EX-99.1	Meridian Bioscience, Inc. Enters into Agreement to Be Acquired by SD Biosensor and SJL Partners in $1.53 Billion All-Cash Transaction Shareholders to Receive $34.00 Per Share in Cash, Providing Immediate, Compelling and Certain Value Transaction Foll Exhibit 99.1 For Immediate Release Meridian Bioscience, Inc. Enters into Agreement to Be Acquired by SD Biosensor and SJL Partners in $1.53 Billion All-Cash Transaction Shareholders to Receive $34.00 Per Share in Cash, Providing Immediate, Compelling and Certain Value Transaction Follows Deliberate Review, Including Outreach to Potential Strategic and Financial Partners CINCINNATI, OHIO & SEOUL, S
July 7, 2022	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State
July 7, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 7, 2022 MERIDIAN BIOSCIENCE, INC.
July 7, 2022	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 7, 2022 MERIDIAN BIOSCIENCE, UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 7, 2022 MERIDIAN BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Ohio 0-14902 31-0888197 (State or Other Jurisdiction of Incorporation) (Commission File N
July 7, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 7, 2022 MERIDIAN BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Ohio 0-14902 31-0888197 (State or Other Jurisdiction of Incorporation) (Commission File N
July 7, 2022	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State
May 27, 2022	SD	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM SD SPECIALIZED DISCLOSURE REPORT MERIDIAN BIOSCIENCE, INC. (Exact Name of Registrant as Specified in Charter) Ohio 0-14902 31-0888197 (State or Other Jurisdiction of Incorpora UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM SD SPECIALIZED DISCLOSURE REPORT MERIDIAN BIOSCIENCE, INC.
May 27, 2022	EX-1.01	Conflict Minerals Report as required by Items 1.01 and 1.02 of this Form. Exhibit 1.01 Meridian Bioscience, Inc. Conflict Minerals Report For the Year Ended December 31, 2021 FORWARD-LOOKING STATEMENTS Forward-looking statements contained in this Conflict Minerals Report (?Report?) are made based on known events and circumstances at the time of release, and as such, are subject in the future to unforeseen uncertainties and risks. Statements in this Report which express
May 6, 2022	EX-99.1	INTERIM UNAUDITED OPERATING RESULTS (In Thousands, Except per Share Data) Exhibit 99.1 For Immediate Release MERIDIAN BIOSCIENCE REPORTS RECORD SECOND QUARTER FISCAL 2022 OPERATING RESULTS CINCINNATI, OHIO May 6, 2022 (PRNewswire) - Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced financial results for the second quarter ended March 31, 2022. Second Quarter Fiscal 2022 Highlights (Comparison to Second Quarter Fiscal 2021): ? Consolidated net revenues totaled $11
May 6, 2022	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 6, 2022 MERIDIAN BIOSCIENCE, INC.
May 6, 2022	10-Q	Table of Contents SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2022 OR ☐ TRANSITION REPORT PURSU Table of Contents SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-14902 MERIDIAN BIOSCIENCE
May 6, 2022	EX-99.2	The Private Securities Litigation Reform Act of 1995 provides a safe harbor from civil litigation for forward-looking statements accompanied by meaningful cautionary statements. Except for historical information, this presentation contains forward-lo FY2022 Q2 Results May 6, 2022 Exhibit 99.2 The Private Securities Litigation Reform Act of 1995 provides a safe harbor from civil litigation for forward-looking statements accompanied by meaningful cautionary statements. Except for historical information, this presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 2
May 2, 2022	EX-99.1	Meridian Acquires EUPROTEIN to Further Expand Recombinant Protein Capabilities Exhibit 99.1 For Immediate Release Meridian Acquires EUPROTEIN to Further Expand Recombinant Protein Capabilities CINCINNATI, OHIO, May 2, 2022 (PRNewswire) ? Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced today that it has acquired, through its subsidiary Meridian Life Science, Inc., substantially all o
May 2, 2022	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 2, 2022 MERIDIAN BIOSCIENCE, INC.
April 7, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 7, 2022 MERIDIAN BIOSCIENCE, INC.
April 7, 2022	EX-99.1	Meridian Bioscience Announces Preliminary Net Revenues Results for Fiscal 2022 Second Quarter Exhibit 99.1 For Immediate Release Meridian Bioscience Announces Preliminary Net Revenues Results for Fiscal 2022 Second Quarter CINCINNATI, OHIO April 7, 2022 (PRNewswire) Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, today provided preliminary net revenues results for its second quarter of fiscal 2022. Prelimin
February 22, 2022	EX-10.1	Andrew S. Kitzmiller Meridian Offer Letter, dated February 8, 2022 (Incorporated by reference to Meridian’s Form 8-K filed with the SEC on February 22, 2022) Exhibit 10.1 3471 River Hills Drive Cincinnati, OH 45244 513-271-3700 Meridianbioscience.com February 8, 2022 Andrew S. Kitzmiller 9287 Steeplechase Drive Cincinnati, OH 45242 Dear Andrew, This letter serves to confirm our offer, of the Chief Financial Officer position with Meridian Bioscience, reporting directly to the Jack Kenny, CEO. Your work location will be 3471 River Hills Dr, Cincinnati, O
February 22, 2022	EX-99.1	Meridian Bioscience Names Andy Kitzmiller as Chief Financial Officer Exhibit 99.1 For Immediate Release Meridian Bioscience Names Andy Kitzmiller as Chief Financial Officer CINCINNATI, OHIO, February 21, 2022 (PRNewswire) ? Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced today that Andy Kitzmiller joined Meridian Bioscience as Executive Vice President and Chief Financial O
February 22, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 21, 2022 MERIDIAN BIOSCIENCE, INC.
February 11, 2022	SC 13G/A	VIVO / Meridian Bioscience, Inc. / Flynn James E Passive Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No.
February 10, 2022	SC 13G/A	VIVO / Meridian Bioscience, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 12)* Name of issuer: Meridian Bioscience Inc. Title of Class of Securities: Common Stock CUSIP Number: 589584101 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is fi
February 4, 2022	EX-10.3	Form of Performance-Based Restricted Share Unit Award Agreement Exhibit 10.3 MERIDIAN BIOSCIENCE, INC. 2021 OMNIBUS AWARD PLAN FISCAL YEAR 2022 PERFORMANCE SHARE UNIT AWARD AGREEMENT CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. [***] Summary of Performance Share Unit Award Grant MERIDIAN BIOSCIENCE, INC. (the ?Company?), pursuant to
February 4, 2022	EX-99.1	FIRST QUARTER FISCAL 2022 UNAUDITED OPERATING RESULTS (In Thousands, Except per Share Data) Exhibit 99.1 For Immediate Release MERIDIAN BIOSCIENCE REPORTS SECOND BEST QUARTER IN COMPANY HISTORY CINCINNATI, OHIO February 4, 2022 (PRNewswire) ? Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced financial results for the first quarter ended December 31, 2021. First Quarter Fiscal 2022 Highlights (Comparison to First Quarter Fiscal 2021): ? Consolidated net revenues of $88.3 million, s
February 4, 2022	EX-99.2	The Private Securities Litigation Reform Act of 1995 provides a safe harbor from civil litigation for forward-looking statements accompanied by meaningful cautionary statements. Except for historical information, this presentation contains forward-lo FY2022 Q1 Results February 4, 2022 Exhibit 99.2 The Private Securities Litigation Reform Act of 1995 provides a safe harbor from civil litigation for forward-looking statements accompanied by meaningful cautionary statements. Except for historical information, this presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Sect
February 4, 2022	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 4, 2022 MERIDIAN BIOSCIENCE, INC.
February 4, 2022	EX-99.1	JOINT FILING AGREEMENT Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13D (including additional amendments thereto) with respect to the Common Shares, no par value, of Meridian Bioscience, Inc., an Ohio corporation. This Joint Filing A
February 4, 2022	10-Q	SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION Table of Contents SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-14902 MERIDIAN BIOSCIE
February 4, 2022	SC 13D	VIVO / Meridian Bioscience, Inc. / Impactive Capital LP - THE SCHEDULE 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO ? 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO ? 240.13d-2(a) (Amendment No. )1 Meridian Bioscience, Inc. (Name of Issuer) Common Shares, no par value (Title of Class of Securities) 589584101 (CUSIP Number) LAUREN TAYLOR WOLFE CHRIS
February 4, 2022	EX-10.1	Chief Executive Officer Cash-Based Incentive Compensation Plan for Fiscal Year 2022 Exhibit 10.1 CASH-BASED INCENTIVE COMPENSATION PLAN FISCAL YEAR 2022 CHIEF EXECUTIVE OFFICER LEVEL 9 CASH-BASED INCENTIVE COMPENSATION PLAN FISCAL YEAR 2022 CHIEF EXECUTIVE OFFICER LEVEL 9 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. [***] I. PURPOSE The purpose of this
February 4, 2022	EX-10.2	Executive Vice President Cash-Based Incentive Compensation Plan for Fiscal Year 2022 Exhibit 10.2 CASH-BASED INCENTIVE COMPENSATION PLAN FISCAL YEAR 2022 EXECUTIVE VICE PRESIDENTS LEVEL 8 CASH-BASED INCENTIVE COMPENSATION PLAN FISCAL YEAR 2022 OFFICERS LEVEL 8 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. [***] I. PURPOSE The purpose of this cash-based i
January 27, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 26, 2022 MERIDIAN BIOSCIENCE, INC.
January 27, 2022	EX-99.1	Meridian Bioscience Elects John C. McIlwraith New Chairman of the Board Exhibit 99.1 For Immediate Release Meridian Bioscience Elects John C. McIlwraith New Chairman of the Board CINCINNATI, OHIO, January 27, 2022 (PRNewswire) ? Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced today that John C. McIlwraith has been elected as Chairman of the Meridian Board of Directors, effect
December 15, 2021	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ___ ) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by
December 15, 2021	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ___ ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
December 2, 2021	EX-99.1	Meridian Bioscience Announces Retirement of CFO Bryan Baldasare Exhibit 99.1 For Immediate Release Meridian Bioscience Announces Retirement of CFO Bryan Baldasare CINCINNATI, OHIO December 2, 2021 (PRNewswire) ? Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced today that Bryan Baldasare, Executive Vice President, Chief Financial Officer, and Secretary, will retire from
December 2, 2021	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 29, 2021 MERIDIAN BIOSCIENCE, INC.
November 23, 2021	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED SEPTEMBER 30, 2021. ☐ TRANSITION REPORT PURSUANT TO SEC Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED SEPTEMBER 30, 2021. ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File No. 0-14902 MERIDIAN BIOSC
November 23, 2021	EX-10.7	Form of Time-Based Restricted Share Unit Award Agreement (Filed herewith) Exhibit 10.7 MERIDIAN BIOSCIENCE, INC. 2021 OMNIBUS AWARD PLAN RESTRICTED SHARE UNIT AWARD AGREEMENT TIME-BASED (U.S. EMPLOYEES) Summary of Restricted Share Unit Award Grant Meridian Bioscience, Inc., an Ohio corporation (the ?Company?), grants to the Grantee named below, in accordance with the terms of the Meridian Bioscience, Inc. 2021 Omnibus Award Plan (the ?Plan?) and this Restricted Share Un
November 23, 2021	EX-21	List of Subsidiaries of the Registrant (Filed herewith) Exhibit 21 Subsidiaries of the Registrant 1. Meridian Bioscience Corporation, an Ohio corporation 2. Meridian Life Science, Inc., a Maine corporation 3. Meridian Bioscience Europe, s.r.l., an Italian corporation 4. Meridian Bioscience Europe S.A., a Belgian corporation 5. Meridian Bioscience Europe B.V., a Dutch corporation 6. Meridian Bioscience UK Ltd., a United Kingdom corporation 7. Meridian B
November 23, 2021	EX-10.8	Form of Nonqualified Stock Option Agreement (Filed herewith) Exhibit 10.8 MERIDIAN BIOSCIENCE, INC. 2021 OMNIBUS AWARD PLAN NONQUALIFIED STOCK OPTION AGREEMENT Summary of Nonqualified Stock Option Grant Meridian Bioscience, Inc., an Ohio corporation (the “Company”), grants to the Grantee named below, in accordance with the terms of the Meridian Bioscience, Inc. 2021 Omnibus Award Plan, a copy of which is available on the Bank of America Merrill Lynch websit
November 12, 2021	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 12, 2021 MERIDIAN BIOSCIENCE, INC.
November 12, 2021	EX-99.2	The Private Securities Litigation Reform Act of 1995 provides a safe harbor from civil litigation for forward-looking statements accompanied by meaningful cautionary statements. Except for historical information, this presentation contains forward-lo EX-99.2 3 d43948dex992.htm EX-99.2 FY2021 Q4 Results November 12, 2021 Exhibit 99.2 The Private Securities Litigation Reform Act of 1995 provides a safe harbor from civil litigation for forward-looking statements accompanied by meaningful cautionary statements. Except for historical information, this presentation contains forward-looking statements within the meaning of Section 27A of the Securiti
November 12, 2021	EX-99.1	FOURTH QUARTER AND FISCAL 2021 UNAUDITED CONDENSED OPERATING RESULTS (In Thousands, Except per Share Data) Exhibit 99.1 For Immediate Release MERIDIAN BIOSCIENCE REPORTS STRONG FOURTH QUARTER AND RECORD FULL-YEAR FISCAL 2021 OPERATING RESULTS AND PROVIDES FISCAL 2022 GUIDANCE CINCINNATI, OHIO November 12, 2021 (PRNewswire) ? Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced financial results for the fourth quarter and fiscal year ended September 30, 2021. Fourth Quarter 2021 Highlights (Comparis
November 10, 2021	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 10, 2021 MERIDIAN BIOSCIENCE, INC.
November 10, 2021	EX-99.1	Meridian Bioscience Receives FDA Emergency Use Authorization for Revogene Exhibit 99.1 For Immediate Release Meridian Bioscience Receives FDA Emergency Use Authorization for Revogene? SARS-CoV-2 Molecular Assay CINCINNATI, November 10, 2021 (PRNewswire) ? Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, today announced that their Revogene? SARS-CoV-2 assay was granted Emergency Use Authorization (EUA) b
October 29, 2021	EX-10.1	Amended and Restated Credit Agreement, dated as of October 25, 2021, by and among Meridian Bioscience, Inc., as Borrower, the Guarantors party thereto, the Lenders party thereto, PNC Bank, National Association, as administrative agent, PNC Capital Markets LLC, as joint lead arranger and sole bookrunner, and Fifth Third Bank, National Association, as joint lead arranger and syndication agent (Incorporated by reference to Meridian’s Form 8-K filed with the SEC on October 29, 2021) Exhibit 10.1 POSTING VERSION DEAL CUSIP NUMBER: 58958EAA7 REVOLVER CUSIP NUMBER: 58958EAB5 $200,000,000 REVOLVING CREDIT FACILITY AMENDED AND RESTATED CREDIT AGREEMENT by and among MERIDIAN BIOSCIENCE, INC., as Borrower, THE GUARANTORS PARTY HERETO, THE LENDERS PARTY HERETO, PNC BANK, NATIONAL ASSOCIATION, as Administrative Agent, PNC CAPITAL MARKETS LLC, as Joint Lead Arranger and Sole Bookrunner
October 29, 2021	8-K	Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 25, 2021 MERIDIAN BIOSCIENCE, INC.
September 1, 2021	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) September 1, 2021 MERIDIAN BIOSCIENCE, INC.
September 1, 2021	EX-99.1	70-6762 EX-99.1 2 d183634dex991.htm EX-99.1 Exhibit 99.1 For Immediate Release Magellan Diagnostics, Inc. Expands Voluntary Recall of LeadCare® Test Kits CINCINNATI, September 1, 2021 (ACCESSWIRE) – Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, today announced its wholly owned subsidiary, Magellan Diagnostics, Inc. (“Magellan”), expand
August 6, 2021	10-Q	SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 O Table of Contents SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-14902 MERIDIAN BIOSCIENCE,
August 6, 2021	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 6, 2021 MERIDIAN BIOSCIENCE, INC.
August 6, 2021	EX-99.2	The Private Securities Litigation Reform Act of 1995 provides a safe harbor from civil litigation for forward-looking statements accompanied by meaningful cautionary statements. Except for historical information, this presentation contains forward-lo EX-99.2 3 d194833dex992.htm EX-99.2 FY2021 Q3 Results August 6, 2021 Exhibit 99.2 The Private Securities Litigation Reform Act of 1995 provides a safe harbor from civil litigation for forward-looking statements accompanied by meaningful cautionary statements. Except for historical information, this presentation contains forward-looking statements within the meaning of Section 27A of the Securities
August 6, 2021	EX-99.1	INTERIM UNAUDITED OPERATING RESULTS (In Thousands, Except per Share Data) Exhibit 99.1 For Immediate Release MERIDIAN BIOSCIENCE REPORTS THIRD QUARTER FISCAL 2021 RESULTS CINCINNATI, OHIO August 6, 2021 (GLOBE NEWSWIRE) ? Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced financial results for the third quarter ended June 30, 2021. Third Quarter 2021 Highlights (Comparison to Third Quarter Fiscal 2020): ? Consolidated net revenues of $63.5 million, down 25% year-o
August 2, 2021	EX-99.1	Meridian Closes Acquisition of BreathTek Exhibit 99.1 For Immediate Release Meridian Closes Acquisition of BreathTek? Business CINCINNATI, OHIO August 2, 2021 (GLOBE NEWSWIRE) ? Meridian Bioscience, Inc., a leading global provider of diagnostic testing solutions and life science raw materials, announced today that it closed the previously announced acquisition of the North American BreathTek? business from Otsuka America Pharmaceutical,
August 2, 2021	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 2, 2021 MERIDIAN BIOSCIENCE, INC.
July 23, 2021	EX-99.1	Meridian Signs Definitive Agreement to Acquire Urea Breath Test for Exhibit 99.1 For Immediate Release Meridian Signs Definitive Agreement to Acquire Urea Breath Test for H. pylori from Otsuka America Pharmaceutical, Inc. CINCINNATI, OHIO July 23, 2021 (GLOBE NEWSWIRE) ? Meridian Bioscience, Inc., a leading global provider of diagnostic testing solutions and life science raw materials, announced today that it signed a definitive agreement to acquire the North Amer
July 23, 2021	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 23, 2021 MERIDIAN BIOSCIENCE, INC.
July 13, 2021	EX-99.1	Meridian Bioscience Announces Preliminary Revenue Results for Fiscal 2021 Third Quarter Exhibit 99.1 For Immediate Release Meridian Bioscience Announces Preliminary Revenue Results for Fiscal 2021 Third Quarter CINCINNATI, OHIO July 13, 2021 (GLOBE NEWSWIRE) Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, today provided preliminary revenue results for its third quarter of fiscal 2021. Preliminary unaudited revenue f
July 13, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 13, 2021 MERIDIAN BIOSCIENCE, INC.
June 28, 2021	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 28, 2021 MERIDIAN BIOSCIENCE, INC.
June 28, 2021	EX-99.1	Meridian Resubmits Application to FDA for Emergency Use Authorization for Revogene EX-99.1 2 d193036dex991.htm EX-99.1 Exhibit 99.1 For Immediate Release Meridian Resubmits Application to FDA for Emergency Use Authorization for Revogene® SARS-CoV-2 Molecular Assay CINCINNATI, OHIO June 28, 2021 (GLOBE NEWSWIRE) – Meridian Bioscience, Inc., a leading global provider of diagnostic testing solutions and life science raw materials, announced today that it has re-submitted its applic
May 27, 2021	EX-1.01	Meridian Bioscience, Inc. Conflict Minerals Report For the Year Ended December 31, 2020 Exhibit 1.01 Meridian Bioscience, Inc. Conflict Minerals Report For the Year Ended December 31, 2020 FORWARD-LOOKING STATEMENTS Forward-looking statements contained in this Conflict Minerals Report (?Report?) are made based on known events and circumstances at the time of release, and as such, are subject in the future to unforeseen uncertainties and risks. Statements in this Report which express
May 27, 2021	SD	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM SD SPECIALIZED DISCLOSURE REPORT MERIDIAN BIOSCIENCE, INC. (Exact Name of Registrant as Specified in Charter) Ohio 0-14902 31-0888197 (State or Other Jurisdiction of Incorpora UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM SD SPECIALIZED DISCLOSURE REPORT MERIDIAN BIOSCIENCE, INC.
May 7, 2021	10-Q	Quarterly Report - 10-Q Table of Contents SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-14902 MERIDIAN BIOSCIENCE
May 7, 2021	EX-99.1	INTERIM UNAUDITED OPERATING RESULTS (In Thousands, Except per Share Data) Exhibit 99.1 For Immediate Release MERIDIAN BIOSCIENCE REPORTS STRONG GROWTH IN NET REVENUES AND EPS IN SECOND QUARTER FISCAL 2021 CINCINNATI, OHIO May 7, 2021 (GLOBE NEWSWIRE) - Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced financial results for the second quarter ended March 31, 2021. Second Quarter 2021 Highlights (Comparison to Second Quarter Fiscal 2020): ? Consolidated net revenue
May 7, 2021	EX-99.2	The Private Securities Litigation Reform Act of 1995 provides a safe harbor from civil litigation for forward-looking statements accompanied by meaningful cautionary statements. Except for historical information, this presentation contains forward-lo FY2021 Q2 Results May 7, 2021 Exhibit 99.2 The Private Securities Litigation Reform Act of 1995 provides a safe harbor from civil litigation for forward-looking statements accompanied by meaningful cautionary statements. Except for historical information, this presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 2
May 7, 2021	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 7, 2021 MERIDIAN BIOSCIENCE, INC.
February 23, 2021	EX-99.1	Meridian Bioscience Provides a Further Update on the Revogene EX-99.1 2 d23318dex991.htm EX-99.1 Exhibit 99.1 For Immediate Release Meridian Bioscience Provides a Further Update on the Revogene® SARS-CoV-2 EUA Submission CINCINNATI, February 23, 2021 (GLOBE NEWSWIRE) – Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, provided a further update on its application for Emergency Use Authorizatio
February 23, 2021	8-K/A	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K/A Amendment No.
February 23, 2021	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 23, 2021 MERIDIAN BIOSCIENCE, INC.
February 23, 2021	EX-99.1	Meridian Bioscience Corrects Prior Update Regarding Revogene EX-99.1 Exhibit 99.1 For Immediate Release Meridian Bioscience Corrects Prior Update Regarding Revogene® SARS-CoV-2 EUA Withdrawal CINCINNATI, February 23, 2021 (GLOBE NEWSWIRE) – Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, updated its communication regarding the withdrawal of its application for Emergency Use Authorization (
February 16, 2021	EX-99.1	Meridian Bioscience Provides an Update on the Revogene Exhibit 99.1 For Immediate Release Meridian Bioscience Provides an Update on the Revogene? SARS-CoV-2 EUA Submission CINCINNATI, February 16, 2021 (GLOBE NEWSWIRE) ? Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, provided an update on its application for Emergency Use Authorization (EUA) with the U. S. Food and Drug Administrati
February 16, 2021	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 16, 2021 MERIDIAN BIOSCIENCE, INC.
February 12, 2021	SC 13G/A	SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 1) * Merid SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No.
February 10, 2021	SC 13G/A	SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 11)* SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 11)* Name of issuer: Meridian Bioscience Inc. Title of Class of Securities: Common Stock CUSIP Number: 589584101 Date of Event Which Requires Filing of this Statement: December 31, 2020 Check the appropriate box to designate the rule pursuant to which this Schedule is fi
February 5, 2021	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 5, 2021 MERIDIAN BIOSCIENCE, INC.
February 5, 2021	EX-10.1	Chief Executive Officer Cash-Based Incentive Compensation Plan for Fiscal Year 2021 EX-10.1 Exhibit 10.1 CASH-BASED INCENTIVE COMPENSATION PLAN FISCAL YEAR 2021 CHIEF EXECUTIVE OFFICER LEVEL 9 CASH-BASED INCENTIVE COMPENSATION PLAN FISCAL YEAR 2021 CHIEF EXECUTIVE OFFICER LEVEL 9 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. [***] I. PURPOSE The purpose
February 5, 2021	EX-10.4	Amendment No. 3 to Share Purchase Agreement dated as of December 21, 2020, between Apres-Demain Inc. (formerly known as GenePOC Inc.), Meridian Bioscience Canada, Inc., Apres-Demain SA in its capacity of Shareholders’ Representative, and Meridian EX-10.4 Exhibit 10.4 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. [***] AMENDMENT NO. 3 TO SHARE PURCHASE AGREEMENT This AMENDMENT NO. 3 TO SHARE PURCHASE AGREEMENT dated as of December 21, 2020, is entered into between APRÈS-DEMAIN DIAGNOSTICS INC. (formerly known as G
February 5, 2021	EX-10.2	Executive Vice President Cash-Based Incentive Compensation Plan for Fiscal Year 2021 EX-10.2 Exhibit 10.2 CASH-BASED INCENTIVE COMPENSATION PLAN FISCAL YEAR 2021 EXECUTIVE VICE PRESIDENTS LEVEL 8 CASH-BASED INCENTIVE COMPENSATION PLAN FISCAL YEAR 2021 OFFICERS LEVEL 8 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. [***] I. PURPOSE The purpose of this cash
February 5, 2021	EX-99.2	The Private Securities Litigation Reform Act of 1995 provides a safe harbor from civil litigation for forward-looking statements accompanied by meaningful cautionary statements. Except for historical information, this presentation contains forward-lo EX-99.2 3 d119657dex992.htm EX-99.2 FY2021 Q1 Results February 5, 2021 Exhibit 99.2 The Private Securities Litigation Reform Act of 1995 provides a safe harbor from civil litigation for forward-looking statements accompanied by meaningful cautionary statements. Except for historical information, this presentation contains forward-looking statements within the meaning of Section 27A of the Securiti
February 5, 2021	10-Q	Quarterly Report - 10-Q Table of Contents SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended December 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-14902 MERIDIAN BIOSCIE
February 5, 2021	EX-99.1	FIRST QUARTER FISCAL 2021 UNAUDITED OPERATING RESULTS (In Thousands, Except per Share Data) EX-99.1 Exhibit 99.1 For Immediate Release MERIDIAN BIOSCIENCE REPORTS RECORD SETTING FIRST QUARTER FISCAL 2021 OPERATING RESULTS AND RAISES FULL YEAR FISCAL 2021 GUIDANCE CINCINNATI, OHIO February 5, 2021 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced financial results for the first quarter ended December 31, 2020. First Quarter 2021 Highlights (Comparison to First Qu
February 5, 2021	EX-10.3	Amendment to Share Purchase Agreement dated as of June 3, 2019, between Apres-Demain Inc. (formerly known as GenePOC Inc.), Meridian Bioscience Canada, Inc., Apres-Demain SA in its capacity of Shareholders’ Representative, and Meridian EX-10.3 Exhibit 10.3 AMENDMENT TO SHARE PURCHASE AGREEMENT This AMENDMENT TO SHARE PURCHASE AGREEMENT (the “Amendment”), dated as of June 3, 2019, is entered into between GENEPOC INC., a corporation incorporated under the laws of Canada (“Seller”), MERIDIAN BIOSCIENCE CANADA INC., a corporation incorporated under the laws of British Columbia (“Buyer”), THE SHAREHOLDERS OF SELLER (the “Shareholders
January 29, 2021	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 27, 2021 MERIDIAN BIOSCIENCE, INC.
January 29, 2021	S-8	- S-8 S-8 As filed with the Securities and Exchange Commission on January 29, 2021 Registration No.
January 29, 2021	EX-10	2021 Omnibus Award Plan EX-10 3 d34197dex10.htm EX-10 Exhibit 10 MERIDIAN BIOSCIENCE, INC. 2021 OMNIBUS AWARD PLAN 1. Purpose. The purpose of the Meridian Bioscience, Inc. 2021 Omnibus Award Plan is to provide a means through which the Company and its Affiliates may attract and retain key personnel and to provide a means whereby directors, officers, employees, consultants and advisors (and prospective directors, officers
January 12, 2021	DEFA14A	- DEFA14A DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (RULE 14A-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐
January 12, 2021	8-K	Other Events - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 12, 2021 MERIDIAN BIOSCIENCE, INC.
January 7, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 7, 2021 MERIDIAN BIOSCIENCE, INC.
January 7, 2021	EX-99.1	Meridian Bioscience Announces Better-than-expected Preliminary First Quarter Fiscal 2021 Revenue Results EX-99.1 Exhibit 99.1 For Immediate Release Meridian Bioscience Announces Better-than-expected Preliminary First Quarter Fiscal 2021 Revenue Results CINCINNATI, January 7, 2021 (GLOBE NEWSWIRE) – Meridian Bioscience, Inc. (NASDAQ: VIVO) a provider of diagnostic testing solutions and life science raw materials, announced preliminary financial results for the first quarter of fiscal 2021. Preliminary
December 30, 2020	DEFA14A	- DEFA14A DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (RULE 14A-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐
December 30, 2020	EX-16.1	Letter from Grant Thornton LLP EX-16.1 Exhibit 16.1 December 28, 2020 U.S. Securities and Exchange Commission Office of the Chief Accountant 100 F Street, NE Washington, DC 20549 Re: Meridian Bioscience, Inc. File No. 0-14902 Dear Sir or Madam: We have read Item 4.01 of Form 8-K of Meridian Bioscience, Inc. dated December 22, 2020, and agree with the statements concerning our Firm contained therein. Very truly yours, /s/ GRANT
December 30, 2020	8-K	Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 22, 2020 MERIDIAN BIOSCIENCE, INC.
December 18, 2020	CORRESP	- Meridian Bioscience, Inc. 3471 River Hills Drive Cincinnati, Ohio 45244 December 18, 2020 Via Edgar 1933 Act Filing Desk Securities and Exchange Commission 450 Fifth Street, N.W. Washington, D.C. 20549 Re: File No. 333-250878 Registration Statement on Form S-3 Filed November 23, 2020 Ladies and Gentlemen: Pursuant to Rule 461 of the Securities Act of 1933, the registrant named below hereby request
December 16, 2020	DEF 14A	- DEF 14A DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.
November 23, 2020	EX-10.16	Amendment No. 2 to Share Purchase Agreement dated as of September 29, 2020, between Apres-Demain Inc. (formerly known as GenePOC Inc.), Meridian Bioscience Canada, Inc., Apres-Demain SA in its capacity of Shareholders’ Representative, and Meridian (Filed herewith) EX-10.16 Exhibit 10.16 AMENDMENT NO. 2 TO SHARE PURCHASE AGREEMENT This AMENDMENT NO. 2 TO SHARE PURCHASE AGREEMENT dated as of September 29, 2020, is entered into between APRÈS-DEMAIN DIAGNOSTICS INC. (formerly known as Genepoc Inc.), a corporation incorporated under the laws of Canada (“Seller”), MERIDIAN BIOSCIENCE CANADA INC., a corporation incorporated under the laws of British Columbia (“Buy
November 23, 2020	10-K	Annual Report - 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED SEPTEMBER 30, 2020. ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File No. 0-14902 MERIDIAN BIOSC
November 23, 2020	S-3	- FORM S-3 Form S-3 Table of Contents As filed with the Securities and Exchange Commission on November 23, 2020 Registration No.
November 23, 2020	EX-10.6	Israeli Appendix to the Meridian Bioscience, Inc. 2012 Stock Incentive Plan dated effective July 10, 2020 (Incorporated by reference to Meridian’s Annual Report on Form 10-K for the Fiscal Year Ended September 30, 2020) EX-10.6 Exhibit 10.6 MERIDIAN BIOSCIENCE, INC. ISRAELI APPENDIX TO THE MERIDIAN BIOSCIENCE, INC. 2012 STOCK INCENTIVE PLAN 1. Special Provisions for Persons who are Israeli Taxpayers. 1.1 This Israeli Appendix (the “Appendix”) to the Meridian Bioscience, Inc. 2012 Stock Incentive Plan, as amended from time to time (the “Plan”) is made and entered effective as of July 10, 2020 (the “Appendix Effect
November 23, 2020	EX-25.1	Statement of Eligibility on Form T-1 under the Trust Indenture Act of 1939, as amended, of U.S. Bank National Association, as Trustee under the Debt Securities Indenture EX-25.1 Exhibit 25.1 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM T-1 STATEMENT OF ELIGIBILITY UNDER THE TRUST INDENTURE ACT OF 1939 OF A CORPORATION DESIGNATED TO ACT AS TRUSTEE ☐ Check if an Application to Determine Eligibility of a Trustee Pursuant to Section 305(b)(2) U.S. BANK NATIONAL ASSOCIATION (Exact name of Trustee as specified in its charter) 31-0841368 I.R.S. Employer
November 23, 2020	EX-10.8	Form of Nonqualified Stock Option Agreement (Filed herewith) EX-10.8 Exhibit 10.8 MERIDIAN BIOSCIENCE, INC. 2012 STOCK INCENTIVE PLAN NONQUALIFIED STOCK OPTION AGREEMENT Summary of Nonqualified Stock Option Grant Meridian Bioscience, Inc., an Ohio corporation (the “Company”), grants to the Grantee named below, in accordance with the terms of the Meridian Bioscience, Inc. 2012 Stock Incentive Plan, a copy of which is available on the Bank of America Merrill
November 23, 2020	EX-4.6	Form of Debt Securities Indenture EX-4.6 Exhibit 4.6 MERIDIAN BIOSCIENCE, INC. INDENTURE Dated as of [ ] U.S. Bank National Association, Trustee TABLE OF CONTENTS Page Article 1 DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1 Definitions 1 Section 1.2 Other Definitions. 5 Section 1.3 Incorporation by Reference of Trust Indenture Act 5 Section 1.4 Rules of Construction. 5 Article 2 THE NOTES 6 Section 2.1 Issuable in Serie
November 23, 2020	EX-10.7	Form of Time-Based Restricted Share Unit Award Agreement (Filed herewith) EX-10.7 Exhibit 10.7 MERIDIAN BIOSCIENCE, INC. 2012 STOCK INCENTIVE PLAN RESTRICTED SHARE UNIT AWARD AGREEMENT TIME-BASED (U.S. EMPLOYEES) Summary of Restricted Share Unit Award Grant Meridian Bioscience, Inc., an Ohio corporation (the “Company”), grants to the Grantee named below, in accordance with the terms of the Meridian Bioscience, Inc. 2012 Stock Incentive Plan (the “Plan”) and this Restric
November 23, 2020	EX-21	List of Subsidiaries of the Registrant (Filed herewith) EX-21 Exhibit 21 Subsidiaries of the Registrant 1. Meridian Bioscience Corporation, an Ohio corporation 2. Meridian Life Science, Inc., a Maine corporation 3. Meridian Bioscience Europe, s.r.l., an Italian corporation 4. Meridian Bioscience Europe S.A., a Belgian corporation 5. Meridian Bioscience Europe B.V., a Dutch corporation 6. Meridian Bioscience UK Ltd., a United Kingdom corporation 7. Meri
November 13, 2020	EX-99.1	FOURTH QUARTER AND FISCAL 2020 UNAUDITED OPERATING RESULTS (In Thousands, Except per Share Data) EX-99.1 Exhibit 99.1 For Immediate Release MERIDIAN BIOSCIENCE REPORTS STRONG FOURTH QUARTER AND RECORD FULL-YEAR FISCAL 2020 OPERATING RESULTS AND PROVIDES FISCAL 2021 GUIDANCE CINCINNATI, OHIO November 13, 2020 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced financial results for the fourth quarter and fiscal year ended September 30, 2020. Fourth Quarter 2020 Highligh
November 13, 2020	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 13, 2020 MERIDIAN BIOSCIENCE, INC.
November 13, 2020	EX-99.2	Forward Looking Statements The Private Securities Litigation Reform Act of 1995 provides a safe harbor from civil litigation for forward-looking statements accompanied by meaningful cautionary statements. Except for historical information, this prese EX-99.2 Exhibit 99.2 FY2020 Q4 & Full Year Results November 13, 2020Exhibit 99.2 FY2020 Q4 & Full Year Results November 13, 2020 Forward Looking Statements The Private Securities Litigation Reform Act of 1995 provides a safe harbor from civil litigation for forward-looking statements accompanied by meaningful cautionary statements. Except for historical information, this presentation contains forw
October 26, 2020	SC 13G	VIVO / Meridian Bioscience, Inc. / Flynn James E Passive Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No.
August 10, 2020	8-K/A	Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K/A Amendment No.
August 7, 2020	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 7, 2020 MERIDIAN BIOSCIENCE, INC.
August 7, 2020	EX-99.1	INTERIM UNAUDITED OPERATING RESULTS (In Thousands, Except per Share Data) EX-99.1 Exhibit 99.1 For Immediate Release MERIDIAN BIOSCIENCE REPORTS FISCAL THIRD QUARTER 2020 OPERATING RESULTS – BEST QUARTER IN COMPANY HISTORY – RAISES FULL YEAR GUIDANCE CINCINNATI, OHIO August 7, 2020 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced financial results for the fiscal third quarter ended June 30, 2020. Third Quarter Fiscal 2020 Highlights: • Consoli
August 7, 2020	10-Q	Quarterly Report - 10-Q Table of Contents SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-14902 MERIDIAN BIOSCIENCE,
August 7, 2020	EX-99.2	The Private Securities Litigation Reform Act of 1995 provides a safe harbor from civil litigation for forward-looking statements accompanied by meaningful cautionary statements. Except for historical information, this presentation contains forward-lo EX-99.2 FY2020 Q3 Results August 7, 2020 Exhibit 99.2 The Private Securities Litigation Reform Act of 1995 provides a safe harbor from civil litigation for forward-looking statements accompanied by meaningful cautionary statements. Except for historical information, this presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, an
July 28, 2020	EX-99.1	Meridian Bioscience Announces New Board Member - Anthony Bihl EX-99.1 Exhibit 99.1 For Immediate Release Meridian Bioscience Announces New Board Member - Anthony Bihl CINCINNATI, July 28, 2020 (GLOBE NEWSWIRE) – Meridian Bioscience, Inc. (NASDAQ: VIVO) announces the appointment of Anthony Bihl III to its Board of Directors, effective immediately. “We welcome Tony to the board as a new independent director and look forward to the leadership he will bring,” sa
July 28, 2020	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 28, 2020 MERIDIAN BIOSCIENCE, INC.
May 27, 2020	EX-1.01	Meridian Bioscience, Inc. Conflict Minerals Report For the Year Ended December 31, 2019 EXHIBIT 1.01 Meridian Bioscience, Inc. Conflict Minerals Report For the Year Ended December 31, 2019 FORWARD-LOOKING STATEMENTS Forward-looking statements contained in this Report are made based on known events and circumstances at the time of release, and as such, are subject in the future to unforeseen uncertainties and risks. Statements in this Report which express a belief, expectation or inte
May 27, 2020	SD	- MERIDIAN BIOSCIENCE, INC. FORM SD UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT MERIDIAN BIOSCIENCE, INC. (Exact name of the registrant as specified in its charter) Ohio 0-14902 31-0888197 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) 3471 River Hills Drive, Cincinnati, Ohio 45244 (Address of principal execut
May 8, 2020	10-Q	Quarterly Report - 10-Q Table of Contents SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-14902 MERIDIAN BIOSCIENCE
May 8, 2020	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 8, 2020 MERIDIAN BIOSCIENCE, INC.
May 8, 2020	EX-99.2	The Private Securities Litigation Reform Act of 1995 provides a safe harbor from civil litigation for forward-looking statements accompanied by meaningful cautionary statements. Except for historical information, this presentation contains forward-lo EX-99.2 FY2020 Q2 Results May 8, 2020 Exhibit 99.2 The Private Securities Litigation Reform Act of 1995 provides a safe harbor from civil litigation for forward-looking statements accompanied by meaningful cautionary statements. Except for historical information, this presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and S
May 8, 2020	EX-99.1	INTERIM UNAUDITED OPERATING RESULTS (In Thousands, Except per Share Data) EX-99.1 Exhibit 99.1 For Immediate Release MERIDIAN BIOSCIENCE REPORTS SECOND QUARTER 2020 OPERATING RESULTS; RAISES GUIDANCE ON STRENGTH OF COVID-19 RELATED PRODUCTS CINCINNATI, OHIO May 8, 2020 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced financial results for the second quarter ended March 31, 2020. Second Quarter Fiscal 2020 Highlights: ● Consolidated Net Revenue
April 30, 2020	EX-99.1	MERIDIAN BIOSCIENCE ANNOUNCES CLOSING OF TRANSACTION TO ACQUIRE EXALENZ BIOSCIENCE EX-99.1 Exhibit 99.1 For Immediate Release MERIDIAN BIOSCIENCE ANNOUNCES CLOSING OF TRANSACTION TO ACQUIRE EXALENZ BIOSCIENCE CINCINNATI, OHIO APRIL 30, 2020 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, has completed its previously announced acquisition of Exalenz Bioscience Ltd., the Modiin, Israel based pr
April 30, 2020	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 30, 2020 MERIDIAN BIOSCIENCE, INC.
April 3, 2020	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 2, 2020 MERIDIAN BIOSCIENCE, INC.
April 3, 2020	EX-99.1	MERIDIAN BIOSCIENCE ANNOUNCES BETTER-THAN-EXPECTED PRELIMINARY SECOND QUARTER FISCAL 2020 REVENUE RESULTS WITH DOUBLE-DIGIT GROWTH EX-99.1 Exhibit 99.1 For Immediate Release MERIDIAN BIOSCIENCE ANNOUNCES BETTER-THAN-EXPECTED PRELIMINARY SECOND QUARTER FISCAL 2020 REVENUE RESULTS WITH DOUBLE-DIGIT GROWTH CINCINNATI, OHIO April 2, 2020 (GLOBE NEWSWIRE) Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, today provided a business update including preliminary revenu
February 20, 2020	EX-10.2	First Amendment and Consent, dated as of February 19, 2020, by and among Meridian Bioscience, Inc., the Guarantors from time to time party thereto, the Lenders from time to time party thereto, and PNC Bank, National Association (Incorporated by reference to Meridian’s Form 8-K filed with the Securities and Exchange Commission on February 20, 2020) EX-10.2 Exhibit 10.2 EXECUTION VERSION FIRST AMENDMENT AND CONSENT THIS FIRST AMENDMENT AND CONSENT, dated as of February 19, 2020 (this “First Amendment”), to the Credit Agreement, dated as of May 24, 2019 (as the same may from time to time be amended, restated, supplemented or otherwise modified from time to time, the “Credit Agreement”), by among others, MERIDIAN BIOSCIENCE, INC., an Ohio corpo
February 20, 2020	EX-10.1	Voting Agreement, dated as of February 19, 2020, by and between Mori Arkin and Meridian Bioscience, Inc. EX-10.1 Exhibit 10.1 VOTING AGREEMENT This Voting Agreement (this “Agreement”), dated as of February 19, 2020, is entered into by and between the undersigned shareholder (“Shareholder”) of EXALENZ BIOSCIENCE LTD., a company organized under the laws of the State of Israel (the “Company”), and MERIDIAN BIOSCIENCE, INC., a company organized under the laws of the State of Ohio (“Parent”). Parent and S
February 20, 2020	8-K	Regulation FD Disclosure, Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 19, 2020 MERIDIAN BIOSCIENCE, INC.
February 20, 2020	EX-2.1	Agreement and Plan of Merger, dated as of February 19, 2020, by and among Meridian Bioscience, Inc., APM Trust Shelf 14 Ltd. and Exalenz Bioscience Ltd. EX-2.1 Exhibit 2.1 Execution Version AGREEMENT AND PLAN OF MERGER by and among MERIDIAN BIOSCIENCE, INC., APM TRUST SHELF 14 LTD. and EXALENZ BIOSCIENCE LTD. Dated as of February 19, 2020 1 TABLE OF CONTENTS Page Article I DEFINITIONS & INTERPRETATIONS 2 Section 1.1 Certain Definitions 2 Section 1.2 Additional Definitions 13 Section 1.3 Certain Interpretations 16 Article II THE MERGER 17 Section 2
February 20, 2020	EX-99.1	MERIDIAN BIOSCIENCE SIGNS DEFINITIVE AGREEMENT TO ACQUIRE EXALENZ BIOSCIENCE; ADDS EX-99.1 5 d894550dex991.htm EX-99.1 Exhibit 99.1 For Immediate Release MERIDIAN BIOSCIENCE SIGNS DEFINITIVE AGREEMENT TO ACQUIRE EXALENZ BIOSCIENCE; ADDS STATE-OF-THE-ART UREA BREATH TEST DIAGNOSTICS PLATFORM CINCINNATI, OHIO AND MODIIN, ISRAEL FEBRUARY 19, 2020 (GLOBE NEWSWIRE) Meridian Bioscience, Inc. (NASDAQ: VIVO) and Exalenz Bioscience Ltd. (TASE: EXEN) announced today that the two companies
February 12, 2020	SC 13G/A	VIVO / Meridian Bioscience, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 10)* Name of issuer: Meridian Bioscience Inc Title of Class of Securities: Common Stock CUSIP Number: 589584101 Date of Event Which Requires Filing of this Statement: December 31, 2019 Check the appropriate box to designate the rule pursuant to which this Schedule is fil
February 7, 2020	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 7, 2020 MERIDIAN BIOSCIENCE, INC.
February 7, 2020	EX-10.1	Cash - Based Incentive Compensation Plan for Fiscal 2020 EX-10.1 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. [***] Exhibit 10.1 CASH-BASED INCENTIVE COMPENSATION PLAN FISCAL YEAR 2020 OFFICERS LEVEL 8 I. PURPOSE The purpose of this cash-based incentive compensation plan (the “Plan”) is to define a mechanism for stimulating a
February 7, 2020	EX-99.1	FIRST QUARTER FISCAL 2020 UNAUDITED OPERATING RESULTS (In Thousands, Except per Share Data) EX-99.1 Exhibit 99.1 For Immediate Release MERIDIAN BIOSCIENCE REPORTS FIRST QUARTER FISCAL 2020 OPERATING RESULTS AND REAFFIRMS 2020 GUIDANCE CINCINNATI, OHIO February 7, 2020 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced financial results for the first quarter ended December 31, 2019. First Quarter Fiscal 2020 Highlights: ● Diagnostics segment delivered nearly $35 m
February 7, 2020	10-Q	Quarterly Report - 10-Q Table of Contents SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-14902 MERIDIAN BIOSCIE
January 30, 2020	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 29, 2020 Meridian Bioscience, Inc.
January 27, 2020	EX-99.1	Meridian Bioscience Lyo-Ready 1-Step RT-qPCR Mix is Used in the Development of Molecular Diagnostics for New Coronavirus Outbreak EXHIBIT 99.1 For Immediate Release Meridian Bioscience Lyo-Ready 1-Step RT-qPCR Mix is Used in the Development of Molecular Diagnostics for New Coronavirus Outbreak CINCINNATI, January 27, 2020 (GLOBE NEWSWIRE) - Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced a novel coronavirus, identified by Chinese authorities on January 7 and currently named 2019-nCoV, is a new strain that had not be
January 27, 2020	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 27, 2020 Meridian Bioscience, Inc.
December 18, 2019	DEF 14A	VIV0 / MERIDIAN BIOSCIENCE INC DEF 14A - - DEF 14A DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.
December 10, 2019	SC 13G/A	VIVO / Meridian Bioscience, Inc. / BROWN CAPITAL MANAGEMENT LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (AMENDMENT NO. 13)* Meridian Bioscience, Inc. (Name of Issuer) Common Shares, No Par Value (Title of Class of Securities) 589584101 (CUSIP Number) Eddie C. Brown Brown Capit
November 26, 2019	EX-21	List of Subsidiaries of the Registrant (Filed herewith) EX-21 Exhibit 21 Subsidiaries of the Registrant 1. Meridian Bioscience Corporation, an Ohio corporation 2. Meridian Life Science, Inc., a Maine corporation 3. Meridian Bioscience Europe, s.r.l., an Italian corporation 4. Meridian Bioscience Europe S.A., a Belgian corporation 5. Meridian Bioscience Europe B.V., a Dutch corporation 6. Meridian Bioscience Asia Pte. Ltd., a Singapore corporation 7. Me
November 26, 2019	EX-3.2	Amended and Restated Code of Regulations (Incorporated by reference to Meridian’s Form 10-K filed with the SEC on November 26, 2019) EX-3.2 Exhibit 3.2 AMENDED AND RESTATED CODE OF REGULATIONS OF MERIDIAN BIOSCIENCE, INC. The Amended Code of Regulations of Meridian Bioscience, Inc. is hereby amended and restated in its entirety by the Board of Directors pursuant to Ohio General Corporation Law Section 1701.11(A)(1)(d) to read as follows as of November 26, 2019. ARTICLE I FISCAL YEAR Unless otherwise designated by resolution of
November 26, 2019	EX-3.1	Amended Articles of Incorporation (Filed herewith) EX-3.1 Exhibit 3.1 AMENDED ARTICLES OF INCORPORATION OF MERIDIAN BIOSCIENCE, INC. MERIDIAN BIOSCIENCE, INC. hereby adopts the following Amended Articles of Incorporation to supercede and take the place of the existing Amended Articles of Incorporation and all Amendments thereto: FIRST. The name of the Corporation is Meridian Bioscience, Inc. SECOND. The place in Ohio where its principal office is
November 26, 2019	EX-4.1	Description of Securities (Incorporated by reference to Meridian’s Form 10-K filed with the SEC on November 26, 2019) EX-4.1 Exhibit 4.1 Description of Registrant’s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 As of November 26, 2019, Meridian Bioscience, Inc. (“we,” “our”) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended, namely, common stock. We also are authorized to issue preferred stock. The description below doe
November 26, 2019	10-K	Annual Report - 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED SEPTEMBER 30, 2019. ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File No. 0-14902 MERIDIAN BIOSC
November 7, 2019	EX-99.1	FOURTH QUARTER AND FISCAL 2019 UNAUDITED OPERATING RESULTS (In Thousands, Except per Share Data) EX-99.1 Exhibit 99.1 For Immediate Release MERIDIAN BIOSCIENCE REPORTS FOURTH QUARTER AND FULL-YEAR FISCAL 2019 OPERATING RESULTS AND PROVIDES FISCAL 2020 GUIDANCE CINCINNATI, OHIO November 7, 2019 (GLOBE NEWSWIRE) - Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced financial results for the fourth quarter and fiscal year ended September 30, 2019. Fourth Quarter 2019 Highlights (Comparison
November 7, 2019	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 7, 2019 MERIDIAN BIOSCIENCE, INC.
November 7, 2019	EX-99.2	Forward Looking Statements The Private Securities Litigation Reform Act of 1995 provides a safe harbor from civil litigation for forward-looking statements accompanied by meaningful cautionary statements. Except for historical information, this prese EX-99.2 Exhibit 99.2Exhibit 99.2 Forward Looking Statements The Private Securities Litigation Reform Act of 1995 provides a safe harbor from civil litigation for forward-looking statements accompanied by meaningful cautionary statements. Except for historical information, this presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amend
November 7, 2019	EX-10.1	Amended and Restated Employment Agreement dated effective October 1, 2019 between Meridian and John P. Kenny (Incorporated by reference to Meridian’s Form 8-K filed with the SEC on November 7, 2019) EX-10.1 Exhibit 10.1 AMENDED AND RESTATED EMPLOYMENT AGREEMENT THIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT (the “Agreement”) is made and entered into as of October 1, 2019, by and between JOHN P. KENNY (the “Executive”) and MERIDIAN BIOSCIENCE, INC., an Ohio corporation (the “Company”). WHEREAS, the Company desires to employ the Executive on the terms and conditions set forth herein; and WHEREA
November 7, 2019	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 5, 2019 MERIDIAN BIOSCIENCE, INC.
October 4, 2019	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 1, 2019 Meridian Bioscience, Inc.
August 14, 2019	EX-99.2	MERIDIAN BIOSCIENCE, INC. AND SUBSIDIARIES Introduction to Unaudited Pro Forma Combined Statement of Operations Year Ended September 30, 2018 (in thousands) EX-99.2 Exhibit 99.2 MERIDIAN BIOSCIENCE, INC. AND SUBSIDIARIES Introduction to Unaudited Pro Forma Combined Statement of Operations Year Ended September 30, 2018 (in thousands) On June 3, 2019, Meridian Bioscience, Inc. (“Meridian”) acquired the business of GenePOC Inc., (“GenePOC”), a Quebec City, Quebec, Canada based provider of molecular diagnostic instruments and assays. The purchase agreemen
August 14, 2019	8-K/A	Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K/A Amendment No.
August 14, 2019	EX-99.1	Business Acquired from GenePOC Inc. Index to Abbreviated Financial Statements Page Report of Independent Certified Public Accountants 1 Statement of Assets Acquired and Liabilities Assumed as of June 3, 2019 2 Statement of Net Revenues and Direct Ope EX-99.1 EXHIBIT 99.1 Business Acquired from GenePOC Inc. Index to Abbreviated Financial Statements Page Report of Independent Certified Public Accountants 1 Statement of Assets Acquired and Liabilities Assumed as of June 3, 2019 2 Statement of Net Revenues and Direct Operating Expenses for the Year Ended December 31, 2018 3 Notes to Abbreviated Financial Statements 4 Report of Independent Certifie
August 7, 2019	10-Q	Quarterly Report - 10-Q Table of Contents SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-14902 MERIDIAN BIOSCIENCE,
July 30, 2019	EX-99.1	INTERIM UNAUDITED OPERATING RESULTS (In Thousands, Except per Share Data) EX-99.1 Exhibit 99.1 For Immediate Release MERIDIAN BIOSCIENCE REPORTS THIRD QUARTER 2019 OPERATING RESULTS CINCINNATI, OHIO July 30, 2019 (GLOBE NEWSWIRE) - Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced financial results for the third quarter and first nine months ended June 30, 2019. Third Quarter 2019 Highlights (Comparison to Third Quarter Fiscal 2018): ● Consolidated revenue decrea
July 30, 2019	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 30, 2019 MERIDIAN BIOSCIENCE, INC.
June 25, 2019	EX-10.1	Separation Agreement and General Release between Meridian Bioscience, Inc. and Eric Rasmussen dated June 21, 2019 (Incorporated by reference to Meridian’s Form 8-K filed with the Securities and Exchange Commission on June 25, 2019) EX-10.1 EXHIBIT 10.1 CONFIDENTIAL SEPARATION AGREEMENT AND GENERAL RELEASE (“Agreement”) Meridian Bioscience, Inc. (“The Company”) and Eric Rasmussen (“You” or “Rasmussen”), agree that: 1. Last Day of Employment. Rasmussen’s last day of employment with the Company is June 21, 2019. Rasmussen’s responsibilities in his current capacity are complete as of June 21, 2019, and this will be termination d
June 25, 2019	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 21, 2019 MERIDIAN BIOSCIENCE, INC.
June 6, 2019	EX-99.1	Forward Looking Statements The Private Securities Litigation Reform Act of 1995 provides a safe harbor from civil litigation for forward-looking statements accompanied by meaningful cautionary statements. Except for historical information, this repor EX-99.1 William Blair Healthcare Conference Jack Kenny, Chief Executive Officer June 6, 2019 Exhibit 99.1 Forward Looking Statements The Private Securities Litigation Reform Act of 1995 provides a safe harbor from civil litigation for forward-looking statements accompanied by meaningful cautionary statements. Except for historical information, this report contains forward-looking statements within
June 6, 2019	8-K	Regulation FD Disclosure, Financial Statements and Exhibits Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 6, 2019 MERIDIAN BIOSCIENCE, INC.
June 3, 2019	EX-99.1	MERIDIAN BIOSCIENCE ANNOUNCES CLOSING OF TRANSACTION TO ACQUIRE BUSINESS OF GENEPOC EX-99.1 Exhibit 99.1 For Immediate Release MERIDIAN BIOSCIENCE ANNOUNCES CLOSING OF TRANSACTION TO ACQUIRE BUSINESS OF GENEPOC CINCINNATI, OHIO June 3, 2019 (GLOBE NEWSWIRE) Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, today announced it has completed its previously announced acquisition of the business of GenePOC Inc., a Queb
June 3, 2019	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Completion of Acquisition or Disposition of Assets Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 3, 2019 MERIDIAN BIOSCIENCE, INC.
June 3, 2019	EX-10.1	Promissory Note dated June 3, 2019 between Meridian Bioscience Canada Inc. and GenePOC Inc. (Incorporated by reference to Meridian’s Form 8-K filed with the Securities and Exchange Commission on June 3, 2019) EX-10.1 Exhibit 10.1 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. [***] PROMISSORY NOTE US$20,000,000 June 3, 2019 MERIDIAN BIOSCIENCE CANADA INC., a legal person governed by the laws of British Columbia and having its principal place of business at 100-360 rue Franquet
May 31, 2019	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 24, 2019 MERIDIAN BIOSCIENCE, INC.
May 31, 2019	EX-10.1	Credit Agreement, dated May 24, 2019 between Meridian Bioscience, Inc., as borrower, the Guarantors from time to time party thereto, the Lenders from time to time party thereto, and PNC Bank, National Association, as administrative agent (Incorporated by reference to Meridian’s Form 8-K filed with the Securities and Exchange Commission on May 31, 2019) EX-10.1 Exhibit 10.1 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. [***] DEAL CUSIP NUMBER: 58958EAA7 REVOLVER CUSIP NUMBER: 58958EAB5 $125,000,000 REVOLVING CREDIT FACILITY CREDIT AGREEMENT by and among MERIDIAN BIOSCIENCE, INC., as Borrower, THE GUARANTORS PARTY HERETO
May 23, 2019	SD	VIV0 / MERIDIAN BIOSCIENCE INC SD - - MERIDIAN BIOSCIENCE, INC. FORM SD UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT MERIDIAN BIOSCIENCE, INC. (Exact name of the registrant as specified in its charter) Ohio 0-14902 31-0888197 (State or other jurisdiction of incorporation or organization) (Commission File Number) (IRS Employer Identification No.) 3471 River Hills Drive, Cincinnati, Ohio 45244 (Address of
May 23, 2019	EX-1.01	Meridian Bioscience, Inc. Conflict Minerals Report For the Year Ended December 31, 2018 EXHIBIT 1.01 Meridian Bioscience, Inc. Conflict Minerals Report For the Year Ended December 31, 2018 FORWARD-LOOKING STATEMENTS Forward-looking statements contained in this Report are made based on known events and circumstances at the time of release, and as such, are subject in the future to unforeseen uncertainties and risks. Statements in this Report which express a belief, expectation or inte
May 7, 2019	EX-2.1	Share Purchase Agreement dated as of April 29, 2019 by and among GenePOC Inc., Meridian Bioscience Canada Inc., the shareholders of GenePOC Inc., Apres-Demain Holding SA, as Shareholders’ Representative, and Meridian Bioscience, Inc. (Incorporated by reference to Meridian’s Quarterly Report on Form 10-Q for the Quarterly Period Ended March 31, 2019) EX-2.1 Exhibit 2.1 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. [***] SHARE PURCHASE AGREEMENT by and among GENEPOC INC. MERIDIAN BIOSCIENCE CANADA INC., The Shareholders of GenePoc Inc., solely for the purposes of Sections 5.03, 8.01 and 10.05 hereof and APRÈS-DEMAIN H
May 7, 2019	10-Q	Quarterly Report - 10-Q 10-Q SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-14902 MERIDIAN BIOSCIENCE, INC. Incorp
April 30, 2019	EX-10.1	Separation Agreement and General Release Agreement between Meridian Bioscience, Inc. and Lawrence Baldini dated April 26, 2019 (Incorporated by reference to Meridian’s Form 8-K filed with the Securities and Exchange Commission on April 30, 2019) EX-10.1 Exhibit 10.1 3471 River Hills Drive Cincinnati, Ohio 45244 513.271.3700 meridianbioscience.com CONFIDENTIALSEPARATION AGREEMENT AND GENERAL RELEASE (“Agreement”) Meridian Bioscience, Inc. (“The Company”) and Lawrence J. Baldini, his heirs, executors, administrators, successors, and assigns (collectively referred to throughout this Agreement as “Employee”), agree that: 1. Last Day of Employ
April 30, 2019	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 26, 2019 MERIDIAN BIOSCIENCE, INC.
April 30, 2019	EX-99.1	INTERIM UNAUDITED OPERATING RESULTS (In Thousands, Except per Share Data) EX-99.1 Exhibit 99.1 For Immediate Release MERIDIAN BIOSCIENCE REPORTS SECOND QUARTER 2019 OPERATING RESULTS, SUSPENDS QUARTERLY CASH DIVIDEND, AND PROVIDES FISCAL 2019 GUIDANCE FOR PENDING ACQUISITION CINCINNATI, OHIO April 30, 2019 (GLOBE NEWSWIRE) - Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced financial results for the second quarter and first six months ended March 31, 2019. Second
April 30, 2019	8-K	Regulation FD Disclosure, Entry into a Material Definitive Agreement, Financial Statements and Exhibits 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 29, 2019 MERIDIAN BIOSCIENCE, INC.
April 30, 2019	EX-99.1	MERIDIAN BIOSCIENCE ANNOUNCES AGREEMENT TO ACQUIRE BUSINESS OF GENEPOC; ADDS EX-99.1 Exhibit 99.1 For Immediate Release MERIDIAN BIOSCIENCE ANNOUNCES AGREEMENT TO ACQUIRE BUSINESS OF GENEPOC; ADDS STATE-OF-THE-ART MOLECULAR DIAGNOSTICS PLATFORM CINCINNATI, OHIO April 30, 2019 (GLOBE NEWSWIRE) Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, today announced it has entered into a definitive agreement to acqu
April 2, 2019	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Results of Operations and Financial Condition SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 1, 2019 MERIDIAN BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Ohio 0-14902 31-0888197 (State or other jurisdiction of incorporation) (Commission File Number) (IRS E
April 2, 2019	EX-99.1	MERIDIAN BIOSCIENCE ANNOUNCES PRELIMINARY SECOND QUARTER 2019 REVENUE RESULTS; UPDATES FISCAL 2019 GUIDANCE EXHIBIT 99.1 . For Immediate Release MERIDIAN BIOSCIENCE ANNOUNCES PRELIMINARY SECOND QUARTER 2019 REVENUE RESULTS; UPDATES FISCAL 2019 GUIDANCE CINCINNATI, OHIO April 2, 2019 (GLOBE NEWSWIRE) Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, today provided a business update including preliminary sales results for its second fiscal
February 14, 2019	SC 13G/A	VIVO / Meridian Bioscience, Inc. / BROWN CAPITAL MANAGEMENT LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (AMENDMENT NO. 12)* Meridian Bioscience, Inc. (Name of Issuer) Common Shares, No Par Value (Title of Class of Securities) 589584101 (CUSIP Number) Eddie C. Brown Brown Capit
February 11, 2019	SC 13G/A	VIVO / Meridian Bioscience, Inc. / VANGUARD GROUP INC Passive Investment meridianbioscienceinc.htm - Generated by SEC Publisher for SEC Filing SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 9 )* Name of issuer: Meridian Bioscience Inc Title of Class of Securities: Common Stock CUSIP Number: 589584101 Date of Event Which Requires Filing of this Statement: December 31, 2018 Check the approp
February 11, 2019	10-Q	VIV0 / MERIDIAN BIOSCIENCE INC 10-Q (Quarterly Report) 10-Q Table of Contents SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended December 31, 2018 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-14902 MERIDIAN BI
January 25, 2019	8-K	Submission of Matters to a Vote of Security Holders SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 24, 2019 MERIDIAN BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Ohio 0-14902 31-0888197 (State or other jurisdiction of incorporation) (Commission File Number) (IR
January 24, 2019	EX-99.2	The Private Securities Litigation Reform Act of 1995 provides a safe harbor from civil litigation for forward-looking statements accompanied by meaningful cautionary statements. Except for historical information, this report contains forward-looking EX-99.2 Exhibit 99.2Exhibit 99.2 The Private Securities Litigation Reform Act of 1995 provides a safe harbor from civil litigation for forward-looking statements accompanied by meaningful cautionary statements. Except for historical information, this report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securi
January 24, 2019	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 24, 2019 MERIDIAN BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Ohio 0-14902 31-0888197 (State or other jurisdiction of incorporation) (Commission File Number)
January 24, 2019	EX-99.1	INTERIM UNAUDITED OPERATING RESULTS (In Thousands, Except per Share Data) EX-99.1 Exhibit 99.1 For Immediate Release MERIDIAN BIOSCIENCE REPORTS FIRST QUARTER 2019 OPERATING RESULTS, DECLARES REGULAR FIRST QUARTER CASH DIVIDEND, AND PROVIDES UPDATED FISCAL 2019 GUIDANCE CINCINNATI, OHIO January 24, 2019 (GLOBE NEWSWIRE) Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced financial results for the first quarter ended December 31, 2018. First Quarter 2019 Highlights:
January 7, 2019	EX-99.1	MERIDIAN BIOSCIENCE ANNOUNCES PRELIMINARY FIRST QUARTER 2019 REVENUE; FIRST QUARTER 2019 FINANCIAL RESULTS CONFERENCE CALL TO BE HELD ON JANUARY 24, 2019 EXHIBIT 99.1 For Immediate Release MERIDIAN BIOSCIENCE ANNOUNCES PRELIMINARY FIRST QUARTER 2019 REVENUE; FIRST QUARTER 2019 FINANCIAL RESULTS CONFERENCE CALL TO BE HELD ON JANUARY 24, 2019 CINCINNATI, OHIO January 7, 2019 (GLOBE NEWSWIRE): Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, announced that it expects first quarter 201
January 7, 2019	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 7, 2019 MERIDIAN BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Ohio 0-14902 31-0888197 (State or other jurisdiction of incorporation) (Commission File Number) (IRS

VIVO / Meridian Bioscience Inc. - تصريحات هيئة الأوراق المالية والبورصات، التقرير السنوي، بيان الوكيل

الإحصائيات الأساسية

SEC Filings

SEC Filings (Chronological Order)